Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 11Gastrointestinal 6Other 4Lymphoid 4Dermatologic 4Genitourinary 3Thoracic 2Other hematologic neoplasm 2Plasma cell 1Other neoplasm 1Head & Neck 1CNS 1

Conditions

Smoldering Multiple Myeloma 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1

Interventions

Dexamethasone 871Bortezomib 457Lenalidomide 456Cyclophosphamide 365Melphalan 272Calcium Dobesilate 263daratumumab 234pomalidomide 208carfilzomib 182fludarabine phosphate 140fludarabine 136Thalidomide 125Peripheral Blood Stem Cell Transplantation 119Filgrastim 114ixazomib 93Mycophenolic Acid 90Granulocyte Colony-Stimulating Factor 89Whole-Body Irradiation 87Busulfan 87dexamethasone acetate 86Tacrolimus 78dexamethasone 21-phosphate 74isatuximab 69Cyclosporine 68auricularum 67Prednisone 65elotuzumab 58belantamab mafodotin 57Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Docosahexaenoic Acids × Plasma cell × Clear all
NCT06055894 2025-11-13

A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)

Memorial Sloan Kettering Cancer Center

Phase NA Recruiting
200 enrolled
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡